Management of Abnormal Potassium and Creatinine Levels

Assessment and Monitoring

The American Diabetes Association recommends regularly monitoring both albuminuria and eGFR annually to enable timely diagnosis of chronic kidney disease (CKD), monitor progression, detect acute kidney injury (AKI), and determine appropriate medication dosing 1, 2
For patients with eGFR <60 mL/min/1.73 m², the American Diabetes Association suggests monitoring serum potassium and creatinine more frequently, especially when using medications that affect potassium levels 1, 3
The frequency of monitoring should follow a risk-based approach: every 6-12 months for stage 3 CKD, every 3-5 months for stage 4 CKD, and every 1-3 months for stage 5 CKD 1
When initiating or adjusting doses of ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists (MRAs), the American College of Physicians recommends checking serum potassium and creatinine within 2-4 weeks 4, 5

The American College of Physicians recommends not discontinuing renin-angiotin system (RAS) inhibitors for mild to moderate increases in serum creatinine (≤30%) in the absence of volume depletion 4, 5, 3
For creatinine increases >30% after starting RAS inhibitors, the American College of Physicians suggests considering dose reduction or temporary withdrawal, especially if accompanied by symptomatic hypotension or AKI 4
The American Diabetes Association advises avoiding nephrotoxic medications (e.g., NSAIDs) in patients with elevated creatinine, particularly those with eGFR <60 mL/min/1.73 m² 1
The American Diabetes Association recommends considering referral to a nephrologist if eGFR <30 mL/min/1.73 m², uncertain etiology of kidney disease, difficult management issues, or rapidly progressing kidney disease 2

For patients who develop hyperkalemia during RAS inhibitor initiation or dose titration, the American College of Physicians recommends considering the following measures: initiate or adjust diuretic therapy 6, use sodium bicarbonate in patients with metabolic acidosis 4, and consider gastrointestinal cation exchangers for persistent hyperkalemia 4
For severe hyperkalemia (>6.5 mEq/L) with ECG changes, the American Diabetes Association suggests implementing emergency measures: administer intravenous dextrose solution with insulin 6, correct acidosis with intravenous sodium bicarbonate if present 4, and consider exchange resins, hemodialysis, or peritoneal dialysis in severe cases 5

For patients with diabetes, hypertension, and albuminuria (ACR >30 mg/g), the American College of Physicians recommends using RAS inhibitors (ACE inhibitors or ARBs) titrated to maximum tolerated dose 4, 2
The American College of Physicians advises avoiding combination therapy with ACE inhibitors and ARBs as this increases hyperkalemia risk without additional benefits 4
For resistant hypertension, the American Diabetes Association suggests considering adding a mineralocorticoid receptor antagonist (MRA) with careful monitoring of potassium levels 6
For patients with type 2 diabetes and CKD, the American Diabetes Association recommends considering SGLT2 inhibitors to reduce CKD progression and cardiovascular events if eGFR ≥20 mL/min/1.73 m² 3
When using diuretics, the American Diabetes Association recommends monitoring for hypokalemia which is associated with cardiovascular risk and mortality 1

In patients receiving multiple medications that affect potassium (ACE inhibitors, ARBs, MRAs), the American Diabetes Association suggests more frequent monitoring of serum potassium and creatinine is required 6
For patients on dialysis, the American Diabetes Association recommends considering higher levels of dietary protein intake (1.0-1.2 g/kg/day) since malnutrition is a major problem 3
For non-dialysis dependent stage 3 or higher CKD, the American Diabetes Association recommends limiting dietary protein intake to 0.8 g/kg body weight per day 3

The American Diabetes Association advises not confusing AKI with expected creatinine increases (up to 30%) when starting RAS blockers 1
The American College of Physicians recommends not discontinuing beneficial medications like RAS inhibitors prematurely due to minor laboratory changes 4
The American Diabetes Association suggests not overlooking the importance of monitoring both potassium and creatinine together, as changes in one often affect the other 1, 2